Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
Yoshio Sumida, Masashi Yoneda, Katsutoshi Tokushige, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 6, pp. 1907-1907
Open Access | Times Cited: 59

Showing 1-25 of 59 citing articles:

The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease
Hideki Fujii, Norifumi Kawada
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 11, pp. 3863-3863
Open Access | Times Cited: 222
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 203
Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging
Anne Flint, Grit Andersen, Paul Hockings, et al.
Alimentary Pharmacology & Therapeutics (2021) Vol. 54, Iss. 9, pp. 1150-1161
Open Access | Times Cited: 145
The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management
Bo Xu, Shaoqian Li, Bo-Kyeong Kang, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 116
GLP-1a: Going beyond Traditional Use
Lucas Fornari Laurindo, Sandra Maria Barbalho, Élen Landgraf Guiguer, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 2, pp. 739-739
Open Access | Times Cited: 71
Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials
Alessandro Mantovani, Christopher D. Byrne, Eleonora Scorletti, et al.
Diabetes & Metabolism (2020) Vol. 46, Iss. 6, pp. 427-441
Open Access | Times Cited: 110
Non-Alcoholic Steatohepatitis (NASH) – A Review of a Crowded Clinical Landscape, Driven by a Complex Disease
Julia M. Fraile, Soumya Palliyil, Caroline J. Barelle, et al.
Drug Design Development and Therapy (2021) Vol. Volume 15, pp. 3997-4009
Open Access | Times Cited: 100
Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)
Stefano Fiorucci, Michele Biagioli, Valentina Sepe, et al.
Expert Opinion on Investigational Drugs (2020) Vol. 29, Iss. 6, pp. 623-632
Closed Access | Times Cited: 85
Berberine prevents NAFLD and HCC by modulating metabolic disorders
Xinyue Lin, Jilei Zhang, Yajun Chu, et al.
Pharmacology & Therapeutics (2024) Vol. 254, pp. 108593-108593
Closed Access | Times Cited: 13
Effects of the SGLT2 inhibitor ipragliflozin and metformin on hepatic steatosis and liver fibrosis: Sub‐analysis of a randomized controlled study
Kiichi Hirayama, Masaya Koshizaka, Ryoichi Ishibashi, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access | Times Cited: 1
GLP-1 Receptor Agonist Effects on Lipid and Liver Profiles in Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis
Shahla Rezaei, Reza Tabrizi, Peyman Nowrouzi‐Sohrabi, et al.
Canadian Journal of Gastroenterology and Hepatology (2021) Vol. 2021, pp. 1-11
Open Access | Times Cited: 42
Novel strategies for glycaemic control and preventing diabetic complications applying the clustering-based classification of adult-onset diabetes mellitus: A perspective
Hayato Tanabe, Hiroaki Masuzaki, Michio Shimabukuro
Diabetes Research and Clinical Practice (2021) Vol. 180, pp. 109067-109067
Open Access | Times Cited: 40
SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease
Luigi Mirarchi, Simona Amodeo, Roberto Citarrella, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3668-3668
Open Access | Times Cited: 26
Mesenchymal Stem Cells (MSCs): A Novel Therapy for Type 2 Diabetes
Shuang Gao, Yuanyuan Zhang, Kaini Liang, et al.
Stem Cells International (2022) Vol. 2022, pp. 1-17
Open Access | Times Cited: 26
Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: An overview and current perspectives
Mengyao Yan, Shuli Man, Long Ma, et al.
Metabolism (2022) Vol. 134, pp. 155264-155264
Closed Access | Times Cited: 25
Insulin resistance and Metabolic dysfunction-associated steatotic liver disease (MASLD): Pathways of action of hypoglycemic agents
Andrea del Carmen Maldonado-Rojas, Julia María Zuarth-Vázquez, Misael Uribe, et al.
Annals of Hepatology (2023) Vol. 29, Iss. 2, pp. 101182-101182
Open Access | Times Cited: 14
Current and new pharmacotherapy options for non-alcoholic steatohepatitis
Yoshio Sumida, Masato Yoneda, Yuji Ogawa, et al.
Expert Opinion on Pharmacotherapy (2020) Vol. 21, Iss. 8, pp. 953-967
Closed Access | Times Cited: 33
Empagliflozin activates Sestrin2-mediated AMPK/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease
Yuting Ma, Guangdong Zhang, Zenggguang Kuang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 21
MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development
Farah Khaznadar, Omar Khaznadar, Ana G. Petrovic, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 7, pp. 6300-6314
Open Access | Times Cited: 4
Bile acids and their receptors in hepatic immunity
Stefano Fiorucci, Silvia Marchianò, Eleonora Distrutti, et al.
Liver Research (2025)
Open Access
Hepatic Antifibrotic Pharmacotherapy: Are We Approaching Success?
Yue Chang, Li Hai
Journal of Clinical and Translational Hepatology (2020) Vol. 8, Iss. 2, pp. 222-229
Open Access | Times Cited: 31
Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update
Areti Sofogianni, Athanasios Filippidis, Lampros Chrysavgis, et al.
World Journal of Hepatology (2020) Vol. 12, Iss. 8, pp. 493-505
Open Access | Times Cited: 30
Sodium-Glucose Co-Transporters Family: Current Evidence, Clinical Applications and Perspectives
Riccardo Nevola, Angela Villani, Simona Imbriani, et al.
Frontiers in Bioscience-Landmark (2023) Vol. 28, Iss. 5, pp. 103-103
Open Access | Times Cited: 10
The impact of sodium glucose co‐transporter 2 inhibitors on non‐alcoholic fatty liver disease
Lampros Chrysavgis, Alkistis‐Maria Papatheodoridi, Antonios Chatzigeorgiou, et al.
Journal of Gastroenterology and Hepatology (2020) Vol. 36, Iss. 4, pp. 893-909
Open Access | Times Cited: 24
Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data
Taeang Arai, Masanori Atsukawa, Akihito Tsubota, et al.
Therapeutic Advances in Endocrinology and Metabolism (2021) Vol. 12
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top